Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy
Status:
Completed
Trial end date:
2021-07-15
Target enrollment:
Participant gender:
Summary
Broadly, the objective of this study is to evaluate the fractional decline of intensity of
tracer uptake measured by SUVmax on 68Ga-PSMA PET/CT in bone metastases from prostate cancer
following treatment with radium-223 as a surrogate marker for tumor cell killing.